Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
Acquisition of shares in this transactionCounterparty株式会社イー・スクエア
Disclosing companySOMAR CORPORATION
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
Manufacture and sale of plasma treatment equipment and related businesses
Location Kumiyama-cho, Kuse-gun, Kyoto PrefectureShare capital ¥10 millionDate of incorporation 30 September 2026
Consideration and expenses
Acquisition priceNot disclosed due to confidentiality obligations with the counterparty
Type of ConsiderationCash (consideration for the share acquisition; amount not disclosed due to confidentiality obligations)
Impact on Business Performance
The impact of this transaction on the Company's consolidated results is expected to be immaterial.
Procedures and assumptions
Valuation methodologyTo be determined following due diligence by a third party and discussions with the counterparty
| Item | Details |
|---|---|
| Transaction name | Acquisition of shares in this transaction |
| Counterparty name | 株式会社イー・スクエア |
| Name of the Subject Company | 株式会社ソマール・アプライド・ラディカルズ |
| Business Description of the Subject Company | Manufacture and sale of plasma treatment equipment and related businesses |
| Location of the Subject Company | Kumiyama-cho, Kuse-gun, Kyoto Prefecture |
| Capital Stock of the Subject Company | ¥10 million |
| Date of Establishment of the Subject Company | 30 September 2026 |
| Acquisition price | Not disclosed due to confidentiality obligations with the counterparty |
| Type of Consideration | Cash (consideration for the share acquisition; amount not disclosed due to confidentiality obligations) |
| Number of shares acquired | 1,000 shares (number of voting rights: 1,000) |
| Voting rights ownership percentage | Before 0.00% → after 100.00% |
| Impact on Business Performance | The impact of this transaction on the Company's consolidated results is expected to be immaterial. |
| Date of board resolution | 28 August 2026 |
| Contract Date | 11 September 2026 |
| Execution Date / Effective Date | 30 September 2026 |
| Valuation methodology | To be determined following due diligence by a third party and discussions with the counterparty |
Items this document does not state (16)
Net Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Independent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To combine the management resources of the two companies, create business synergies, strengthen the earnings base and enhance corporate value.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.